2019
National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.
Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.Peer-Reviewed Original ResearchUse of NACUrothelial cell carcinomaReceipt of NACNeoadjuvant chemotherapyMicropapillary variantPathologic responseEntire cohortCell carcinomaClinical stage II diseasePropensity scoreVariant urothelial carcinomaNational Cancer DatabaseStage II diseaseComplete pathologic responsePathologic complete responseAggressive clinical behaviorLogistic regression modelsCT2 diseasePT0 rateComplete responsePathologic characteristicsRadical cystectomyDistant metastasisHistological diagnosisNAC use
2018
Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panel